Congenital myopathy
RecruitingA study to evaluate the safety and effectiveness of surlorian in adults with RYR1-related myopathy
- Disease:Congenital myopathy
- Substances:–
France- Participants:18–64 years · 65+ years
- Sponsor:Rycarma Therapeutics Inc.
Rare diseases
Investigational molecules
Locations

200 Clarendon Street, 02116-5021, United States
Rycarma Therapeutics Inc. focuses on autosomal dominant RYR1-related myopathy, with interest in muscle function, weakness, and fatigability in adult patients. The clinical programme includes evaluation of skeletal muscle performance and related functional outcomes.
The research activity includes assessment of treatment effects on day-to-day physical performance in a rare inherited myopathy.
Rycarma Therapeutics Inc. runs clinical trials in conditions such as Congenital myopathy, among others.
Clinical trials run by this sponsor – those enrolling participants first.
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.